Press release
Expected Growth in Blood Cancer Drugs Market From 2017-2025: Trend, Analysis By Manufacturers, Regions, Type And Application | Global Manufacturer are Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Ro
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-free-sample
Some of the key players in the global market include:
Johnson & Johnson Inc.
Amgen Inc.
Bayer AG.
Pfizer, Inc.
AbbVie Inc.
Roche Holding AG.
Celgene Corporation
AstraZeneca
Novartis AG
GlaxoSmithKline PLC
Merck & Co., Inc.
Eli Lily & Co.
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs.
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
Make an inquiry for purchasing this report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/inquire-before-buying
On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.
Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.
Browse Complete Report Summary @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/
Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Contact us-
Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Expected Growth in Blood Cancer Drugs Market From 2017-2025: Trend, Analysis By Manufacturers, Regions, Type And Application | Global Manufacturer are Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Ro here
News-ID: 1350138 • Views: …
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of …
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. It…
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 …
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected to…
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin …
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billion…
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 …
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reach…
More Releases for Asia
Asia Private Equity Firm, Asia Private Equity Management, Asia Private Equity Se …
The private equity market in China has been rapidly growing in recent years. Private equity (PE) refers to the purchase of shares in a company that are not publicly traded on a stock exchange. PE firms typically target companies that are undervalued or in need of capital for growth, and aim to improve the company's operations and financial performance before selling it at a higher value.
https://boomingfaucet.com/
Asia Private Equity Consulting
E-mail:nolan@pandacuads.com
In China,…
South East Asia Business Jet Market And Top Key Players are Asia Corporate Jet, …
By 2022, the South East Asia Business Jet Markets estimated to reach US$ XX Mn, up from US$ XX Mn in 2016, growing at a CAGR of XX% during the forecast period. The Global Business Jet Market, currently at 21 million USD, contributes the highest share in the market and is poised to grow at the fastest rate in the future. The three broad categories of business jets are Small,…
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022.
23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property…
PEOPLEWAVE WINS ASIA TECH PODCAST PITCHDECK ASIA 2019 AWARDS
15 January 2019, Singapore – Peoplewave, Asia’s leading data-driven HR technology company, won the Asia Tech Podcast (ATP) Pitchdeck Asia 2019 Awards, being awarded “Startup Most Likely to Succeed in 2019".
The 2019 Pitchdeck Asia Awards is an opportunity for the Asian Startup Ecosystem to shine a spotlight on some of its best startups. The awards were decided by a public vote. More than 7,200 votes were cast by registered LinkedIn…
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia
Equipping Asia’s navies with the latest diving technology for asymmetric warfare and
operations
SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is
seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting…
Asia Diligence – Specialist Investigative Due Diligence for Asia & Beyond
Asia Diligence today announced the opening of its European Customer Services office in the United Kingdom. The office is to be managed by Steve Fowler and will focus on providing services to Asia Diligence’s European customers. Asia Diligence is also planning to open a US office in the near future, which will provide customer service to its US and North American clients.
Asked to comment on the move, Luke Palmer, the…
